Eaton, C., Wells, J., Holen, I., Croucher, P., & Hamdy, F. (2004). Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
Chicago Style (17th ed.) CitationEaton, C., J. Wells, I. Holen, P. Croucher, and F. Hamdy. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
ציטוט MLAEaton, C., et al. Serum Osteoprotegerin (OPG) Levels Are Associated with Disease Progression and Response to Androgen Ablation in Patients with Prostate Cancer. 2004.
אזהרה: ציטוטים אלה לעיתים לא מדויקים ב 100%.